Artelo Biosciences Inc (ARTL) has a current Price-to-Book (P/B) ratio of -3.12. Compared to its 3-year average P/B ratio of -0.19, the current P/B ratio is approximately 1557.99% higher. Relative to its 5-year average P/B ratio of 0.36, the current P/B ratio is about -955.14% higher. Artelo Biosciences Inc (ARTL) has a Forward Free Cash Flow (FCF) yield of approximately -318.90%. Compared to its 3-year average FCF yield of -182.96%, the current FCF yield is approximately 74.30% lower. Relative to its 5-year average FCF yield of -128.32%, the current FCF yield is about 148.51% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ARTL competitors is 0.06, providing a benchmark for relative valuation. Artelo Biosciences Inc Corp (ARTL.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ARTL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ARTL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ARTL currently overvalued or undervalued?

What is Artelo Biosciences Inc (ARTL) fair value?

ARTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Artelo Biosciences Inc (ARTL) is between to according to relative valuation method.

How does ARTL's valuation metrics compare to the industry average?

The average P/S ratio for ARTL's competitors is 0.06, providing a benchmark for relative valuation. Artelo Biosciences Inc Corp (ARTL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Artelo Biosciences Inc (ARTL) as of Mar 02 2026?

As of Mar 02 2026, Artelo Biosciences Inc (ARTL) has a P/B ratio of -3.12. This indicates that the market values ARTL at -3.12 times its book value.

What is the current FCF Yield for Artelo Biosciences Inc (ARTL) as of Mar 02 2026?

As of Mar 02 2026, Artelo Biosciences Inc (ARTL) has a FCF Yield of -318.90%. This means that for every dollar of Artelo Biosciences Inc's market capitalization, the company generates -318.90 cents in free cash flow.

What is the current Forward P/E ratio for Artelo Biosciences Inc (ARTL) as of Mar 02 2026?

As of Mar 02 2026, Artelo Biosciences Inc (ARTL) has a Forward P/E ratio of -0.23. This means the market is willing to pay $-0.23 for every dollar of Artelo Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Artelo Biosciences Inc (ARTL) as of Mar 02 2026?

As of Mar 02 2026, Artelo Biosciences Inc (ARTL) has a Forward P/S ratio of 0.00. This means the market is valuing ARTL at $0.00 for every dollar of expected revenue over the next 12 months.

ARTL Valuation